BMY vs MDAI: Which Is the Better Buy in 2026?

Same yardstick, side by side (as of August 2026). Valuation lined up like this is most meaningful for two names in the same corner of the market, which these are. Figures are approximate; verify before investing.

The metrics above tell you which is the marginally better business. The bigger risk for most people is not picking the slightly worse stock, it is over-concentrating. BMY and MDAI share themes, so owning both, or adding either to what you already hold, can quietly push a large share of your portfolio into one bet.

This is the part a generic comparison page cannot answer, because it depends on what you own. Connect your brokerage and Walnut shows your real, combined BMY and MDAI exposure, flags overlap with your existing positions, and tells you if adding one would tip you past a concentration you are comfortable with, read-only by default, with your login staying at your broker. Walnut is not an investment adviser.

Bristol Myers Squibb is one of the largest global biopharmaceutical companies, developing and selling prescription medicines across oncology, hematology, immunology, cardiovascular, and neuroscience. It makes money primarily by selling patented branded drugs, with a portfolio that has historically leaned on blockbuster franchises such as the blood thinner Eliquis (co-marketed with Pfizer), the cancer immunotherapy Opdivo, and the multiple myeloma drug Revlimid. The company is navigating a major patent cliff as several legacy products lose exclusivity, and it is rebuilding growth through a newer portfolio that includes drugs like Reblozyl, Opdualag, Camzyos, Sotyktu, and the schizophrenia treatment Cobenfy (acquired through Karuna). Bristol Myers grows both organically through its research pipeline and through large acquisitions (Celgene, MyoKardia, Karuna, Mirati). It is headquartered in New York and operates worldwide.

Full BMY guide

Spectral AI, Inc. (NASDAQ: MDAI), based in Dallas, Texas, is an artificial-intelligence medical-technology company focused on wound care. Its flagship DeepView System uses multispectral imaging and a proprietary deep-learning algorithm to assess the healing potential of burns and other wounds, delivering an AI-driven tissue classification in roughly 20 to 25 seconds after a sub-second image capture, without touching the patient. The algorithm was trained and validated on a large proprietary database of clinically labeled burn-wound images. The goal is to give clinicians in burn centers, trauma centers, and emergency departments an objective read on which tissue will heal on its own and which requires surgical intervention, a judgment that has traditionally relied on subjective visual inspection.

Full MDAI guide

Both fit overlapping themes, but they are not interchangeable. The useful comparison is which set of drivers and risks you want exposure to.

• BMY drivers: New product portfolio ramp; Oncology and immunology depth.
• MDAI drivers: FDA clearance opens the U.S. market; Non-dilutive government funding.

A faster-growing, richer-valued name usually swings harder, so it suits a longer horizon and a higher tolerance for volatility; a steadier, more cash-generative business suits a more conservative or income-minded investor. The honest test is which set of risks you could hold through a drawdown: The central risk is the patent cliff: Eliquis, Opdivo, and other large products face loss of exclusivity, and generic or biosimilar competition can erode revenue quickly. For MDAI, the risks are substantial and concentrated.

Growth-minded investors who believe the theme has years to run tend to accept the richer multiple for more upside; value-minded investors lean toward the cheaper forward earnings and steadier profile. Pick BMY if you believe its drivers more; MDAI if you believe its. Many investors hold both, but since they share themes, that is a concentrated bet, not diversification. Decide deliberately and check overlap. For the full detail, see the BMY and MDAI guides.

BMY. Bristol Myers tends to trade at a low forward earnings multiple relative to large-cap pharma peers, reflecting market skepticism about its ability to replace patent-cliff revenue. The high dividend yield and strong free cash flow are the bull-case anchors, while the depressed valuation reflects the bear case that legacy declines outrun newer products.

MDAI. Spectral AI should be read as a pre-commercial, development-stage company rather than a normal operating business. Almost all of its reported revenue is research-and-development funding reimbursed under government contracts, chiefly BARDA, so the top line reflects grant-funded development rather than product sales, and it can fall when a contract phase completes (as it did in Q1 2026). Earnings are negative and lumpy, so a P/E ratio is not meaningful, and the market cap reflects expectations for commercializing DeepView, not current profits. All figures are approximate as of the dates noted and change each quarter; verify against Spectral AI's investor relations page or your broker.

Headline figures (approximate, early 2026): BMY shows revenue (ttm) ~$48 billion, operating margin ~20% (varies with acquisition charges), net income (ttm) volatile, pressured by large acquisition write-offs, dividend yield ~4-5%; MDAI shows revenue (fy2025, mostly research/barda) ~$19.7 million R&D revenue, down from ~$29.6 million in 2024, net loss (fy2025) ~$7.6 million net loss for the full year, revenue (q1 2026) ~$4.0 million, down ~40% year over year as BARDA work shifted phases, net loss (q1 2026) ~$3.4 million, versus net income of ~$2.9 million a year earlier.

BMY and MDAI are related but distinct: same themes, different businesses and risks. Neither wins in the abstract; the right pick is whichever thesis you actually believe, sized so you are not over-concentrated in one theme. Walnut can show your combined BMY and MDAI exposure against your real portfolio. It is not an investment adviser.